Publications
-
Mora J, Rodriguez E, de Torres C, Cardesa-Salzmann TM, Ríos J, Hernández T, Cardesa A and de Alava E.
Activated growth signaling pathway expression in Ewing sarcoma and clinical outcome
PEDIATRIC BLOOD & CANCER . 58(4): 532-538. Number of citations: 22
-
Fernandez AF, Assenov Y, Martin-Subero JI, Balint B, Siebert R, Taniguchi H, Yamamoto H, Hidalgo M, Tan AC, Galm O, Ferrer I, Sanchez-Cespedes M, Villanueva A, Carmona J, Sanchez-Mut JV, Berdasco M, Moreno V, Capella G, DAVID NICHOLAS MONK, Ballestar E, Ropero S, Martinez R, Sanchez-Carbayo M, Prosper F, Agirre X, Fraga MF, Graña O, Perez-Jurado L, Mora J, Puig S, Prat J, Badimon L, Puca AA, Meltzer SJ, Lengauer T, Bridgewater J, Bock C and Esteller M.
A DNA methylation fingerprint of 1628 human samples
GENOME RESEARCH . 22(2): 407-419. Number of citations: 331
-
Mora J.
Avenços i controvèrsies en el tractament del neuroblastoma d’alt risc
Pediatría Catalana . 71: 62-69.
-
Acosta S, Mayol G, Rodriguez E, Lavarino C, de Preter K, Kumps C, Garcia I, de Torres C and Mora J.
Identification of tumoral glial precursor cells in neuroblastoma
CANCER LETTERS . 312(1): 73-81. Number of citations: 12
-
Conde N, Cruz-Martínez O, Albert A and Mora J.
Antiangiogenic Treatment as a Pre-Operative Management of Alveolar Soft-Part Sarcoma
PEDIATRIC BLOOD & CANCER . 57(6): 1071-1073. Number of citations: 16
-
Mora J, de Torres C, Parareda A, Torner-Rubies F, Galván P, Rodriguez E, Cardesa-Salzmann TM, Salvador-Hernandez H, Suñol M, Huguet R and Cruz-Martínez O.
Treatment of Ewing Sarcoma Family of Tumors With a Modified P6 Protocol in Children and Adolescents
PEDIATRIC BLOOD & CANCER . 57(1): 69-75. Number of citations: 12
-
Mora J.
¿Por qué la quimioterapia no cura a todos los pacientes con cáncer?
Anales de Pediatría Continuada . 9(3): 191-196.
-
Garcia I, Mayol G, Rodriguez E, Suñol M, Gershon TR, Ríos J, Cheung NK, Kieran MW, George RE, Perez-Atayde AR, Casalà C, Galván P, de Torres C, Mora J and Lavarino C.
Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma
MOLECULAR CANCER . 9: 277-277. Number of citations: 58
-
Royer-Pokora B, Busch M, Beier M, Duhme C, de Torres C, Mora J, Brandt A and Royer HD.
Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm
HUMAN MOLECULAR GENETICS . 19(9): 1651-1668. Number of citations: 61
-
De Preter K, Vermeulen J, Brors B, Delattre O, Eggert A, Fischer M, Janoueix-Lerosey I, Lavarino C, Maris JM, Mora J, Nakagawara A, Oberthuer A, Ohira M, Schleiermacher G, Schramm A, Schulte JH, Wang Q, Westermann F, Speleman F and Vandesompele J.
Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature
CLINICAL CANCER RESEARCH . 16(5): 1532-1541. Number of citations: 76